Investor Relations

Investor FAQs

Please find answers to Frequently Asked Questions here. For additional questions, please contact our IR team at

Where can I find IRS 2014 Form 8937?

Form 8937
During the year ended December 31, 2014, Paratek Pharmaceuticals, Inc., took certain organizational actions that affected the basis of holders of our securities. The Forms 8937 included [below] summarize the impact of those changes and were filed with the Internal Revenue Service. Prior to October 30, 2014, the name of the Company was Transcept Pharmaceuticals, Inc. (“Transcept”). On October 30, 2014, Transcept completed its business combination with Paratek Pharmaceuticals, Inc. (“Old Paratek”) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014, by and among Transcept, Tigris Merger Sub, Inc. (“Merger Sub”), Tigris Acquisition Sub, LLC (“Merger LLC”) and Paratek (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Paratek, with Paratek surviving as a wholly-owned subsidiary of Transcept (the “Merger”), followed by the merger of Paratek with and into Merger LLC, with Merger LLC surviving as a wholly-owned subsidiary of Transcept. Also on October 30, 2014, in connection with, and prior to the completion of, the Merger, Transcept effected a 1-for-12 reverse stock split of its common stock (the “Reverse Stock Split”), and immediately following the Merger, Transcept changed its name to “Paratek Pharmaceuticals, Inc.”, and Merger LLC changed its name to “Paratek Pharma, LLC.” Following the completion of the Merger, the business conducted by Paratek Pharmaceuticals Inc. became primarily the business conducted by Paratek.

Immediately prior to the Merger, Old Paratek sold 8,068,766 shares of its common stock for an aggregate purchase price of $93.0 million to certain existing Paratek stockholders and certain new investors in Paratek (the “Financing”). Immediately prior to the closing of the Financing, the $6.0 million in aggregate principal amount outstanding under, and all accrued interest on, certain notes payable issued in 2014 converted into 1,335,632 shares of Old Paratek’s common stock based on a conversion price of $0.778 per share. Further, and also immediately prior to the closing of the Financing, each share of Old Paratek’s preferred stock outstanding at that time was converted into shares of Old Paratek’s common stock at a ratio determined in accordance with Paratek’s certificate of incorporation then in effect.

Under the terms of the Merger Agreement, Transcept issued shares of its common stock to Old Paratek’s stockholders, at an exchange rate of 0.0675 shares of common stock, after taking into account the Reverse Stock Split, in exchange for each share of Old Paratek common stock outstanding immediately prior to the Merger.


Who is Paratek’s Transfer Agent?

American Stock Transfer & Trust Company, LLC
Shareholder Services
6201 Fifteenth Avenue
Brooklyn, NY 11219
Toll-free: 1-800-937-5449
World Wide: (718) 921-8124


Who are the company’s independent auditors?

Our independent auditor is:

Ernst & Young LLP
255 Main Street
Cambridge, MA 02142
+1 617 374 6200


When does Paratek’s Fiscal Year end?

Our fiscal year ends on December 31.


On what stock exchange are Paratek Shares Traded, What is the Ticker Symbol and CUSIP?

Paratek’s stock is traded on the NASDAQ Global Market under the symbol PRTK. The CUSIP number for Paratek common stock is 699374302.


Where is Paratek Pharmaceuticals’ Corporate Headquarters?

Paratek’s headquarters are located at 75 Park Plaza, 3rd Floor, Boston, MA, 02116. The main office phone number is (617) 807-6600.